This is what analysts have to say about The Medicines Company (NASDAQ:MDCO) after last week.

September 15, 2018 - By Catherine Diaz

The Medicines Company (NASDAQ:MDCO) LogoInvestors sentiment increased to 1.09 in Q2 2018. Its up 0.07, from 1.02 in 2018Q1. It increased, as 24 investors sold The Medicines Company shares while 51 reduced holdings. 27 funds opened positions while 55 raised stakes. 89.10 million shares or 2.14% less from 91.05 million shares in 2018Q1 were reported.
Pinebridge Limited Partnership reported 57,426 shares stake. Partner Fund Management L P holds 1.2% in The Medicines Company (NASDAQ:MDCO) or 2.09 million shares. Parametric Port Ltd Liability Com invested in 0% or 118,279 shares. Us Bancorp De holds 2,981 shares. Moreover, State Board Of Administration Of Florida Retirement System has 0% invested in The Medicines Company (NASDAQ:MDCO). Raymond James And Associate reported 0% in The Medicines Company (NASDAQ:MDCO). Rock Springs Capital Mngmt Lp holds 690,000 shares. Northern accumulated 911,173 shares or 0.01% of the stock. Aperio Limited Liability Com stated it has 0% in The Medicines Company (NASDAQ:MDCO). Teachers Retirement System Of The State Of Kentucky reported 44,694 shares stake. Putnam Invs Limited Liability Company stated it has 0.19% of its portfolio in The Medicines Company (NASDAQ:MDCO). Ameriprise Fincl Incorporated accumulated 0.01% or 540,597 shares. Art Advsr Limited accumulated 21,200 shares or 0.03% of the stock. Bailard accumulated 32,500 shares or 0.07% of the stock. Deutsche Retail Bank Ag invested in 157,940 shares or 0% of the stock.

Since March 21, 2018, it had 0 insider buys, and 4 selling transactions for $4.25 million activity. MEANWELL CLIVE had sold 50,000 shares worth $1.80M on Monday, July 2. The insider CROUSE WILLIAM sold 7,500 shares worth $241,950.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 3 analysts covering Medicines Co (NASDAQ:MDCO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Medicines Co had 3 analyst reports since March 22, 2018 according to SRatingsIntel. Citigroup maintained the shares of MDCO in report on Monday, August 20 with “Buy” rating. On Thursday, March 22 the stock rating was maintained by Oppenheimer with “Buy”. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Wednesday, June 6 by FBR Capital. Below is a list of The Medicines Company (NASDAQ:MDCO) latest ratings and price target changes.

20/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $40 New Target: $50 Maintain
06/06/2018 Broker: FBR Capital Rating: Buy New Target: $55.0000 Initiate
22/03/2018 Broker: Oppenheimer Rating: Buy Maintain

The stock decreased 1.10% or $0.38 during the last trading session, reaching $34.06. About 725,115 shares traded. The Medicines Company (NASDAQ:MDCO) has declined 1.05% since September 15, 2017 and is downtrending. It has underperformed by 16.67% the S&P500.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company has market cap of $2.51 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It currently has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

Another recent and important The Medicines Company (NASDAQ:MDCO) news was published by which published an article titled: “Premarket analyst action – healthcare” on August 20, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.